Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:30 ET
|
Neuronetics
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar® TMS Advances Treatment for Adolescents During Mental Health Awareness Month
May 01, 2024 08:31 ET
|
Neuronetics
MALVERN, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
April 23, 2024 16:30 ET
|
Neuronetics
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
April 10, 2024 08:31 ET
|
Neuronetics
MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Electroceuticals/Bioelectric Medicine Market is Expected to Reach $33.6 billion | MarketsandMarkets™
April 02, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, April 02, 2024 (GLOBE NEWSWIRE) -- Electroceuticals/Bioelectric Medicine market in terms of revenue was estimated to be worth $23.9 billion in 2024 and is poised to reach $33.6 billion by...
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 27, 2024 16:30 ET
|
Neuronetics
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
March 25, 2024 08:30 ET
|
Neuronetics
MALVERN, Pa., March 25, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Announces 5-Year Exclusive Partnership with Transformations Care Network
March 07, 2024 08:22 ET
|
Neuronetics
MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of...
Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
March 05, 2024 07:30 ET
|
Neuronetics
MALVERN, Pa., March 05, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of...
Neuromodulation Market is Expected to Reach $11.0 Billion | MarketsandMarkets™
February 22, 2024 07:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Neuromodulation market in terms of revenue was estimated to be worth $6.2 billion in 2023 and is poised to reach $11.0 billion by 2028, growing at a CAGR...